PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Nxera Pharma UK Limited

USPTO PatentsView assignee record - 12 granted patents across 5 technology areas, recorded in grant years 2024–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

RSS updates for this company
Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Nxera ranks #23,116 of 49,997 tracked US assignees by granted-patent volume, with 12 patents across 5 technology areas.

#23,116
of 49,997 US assignees by volume
Top 34%
by Innovation Score (40.9/100)
18.0
avg claims per patent

USPTO PatentsView assignee plate

Corpus R23116 · Foreign Corporation #23,116 · 12 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

  • GRANTS-MICRO 12 grants
  • MID-PACK #23,116/49,997
  • PHOTO-FINISH Novelda AS
  • CPC-NARROW C07D · 5 areas
  • INNOV-PAR 40.9/100
  • CLAIMS-RICH 18.0 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • SPAN-YRS 2024–2025 · 2y
  • BOOK-RICH 9/10 fields

Nearest grant-volume peer: Novelda AS (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Nxera’s 40.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Nxera

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Nxera's Innovation Score is 40.9/100 (top 34% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Nxera?

Each dot is one of Nxera’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Nxera’s own 18.0 claims/patent is ABOVE the 13.6 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Nxera vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 11.911.91212.1 510152025 Granted patents (volume) Avg claims / patent Novelda AS - 12, 21.08Novelda ASNuLabel Technologies, Inc. - 12, 18.08NulabelNumab Therapeutics AG - 12, 17.42Numab TherapeuticsNura Holdings Pty Ltd - 12, 22.67Nura Holdings PtyObschestvo S Ogranichennoi Otvetstvennostyu “WELDUP” - 12, 11.08Obschestvo S Ogra…OCM Inc. - 12, 6.83OCMOfficine Maccaferri S.P.A. - 12, 12.25Officine Maccafer…Oleon NV - 12, 13.58OleonNxera Pharma UK Limited - 12, 18Nxera Pharma UK
Nxera vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Nxera's grants concentrate

Nxera Pharma UK Limited is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under C07D (Heterocyclic Compounds). By volume, Nxera sits between Novelda AS and Oleon NV.

Nxera's three-year grant acceleration

Nxera Pharma UK Limited shows 2 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Nxera's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Nxera holds 12 patents at rank #23,109, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Nxera

By rank, the assignees closest to #23,109 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Nxera's primary technology class.

Nxera's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

41 Top 34% higher than 66% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

024681012 20242025 10
USPTO utility patent grants by year · 2024–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2024–2019 baseline. Full figures in the table below.

View data table
Nxera Pharma UK Limited patent grants by year, 2015–2025
Year Patents Granted Share of Period
2024 2 16.7%
2025partial year 10 83.3%

Which technologies does Nxera Pharma UK Limited patent most?

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Nxera Pharma UK Limited's patent record in context - here's where to go next.

  • Nxera Pharma UK Limited's lead technology class is C07D (Heterocyclic Compounds), 100% of its portfolio - see every assignee active in that class. Explore C07D
  • Ranked #23,116 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Nxera Pharma UK Limited against Novelda AS, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 40.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.